This is a niche sector starch manfactures caters to following industries
Industry & Application based bifurcation
• Paper Application:
Widely used in paper industry to give strength, surface fuzz and stiffness to paper. It is used to improve the writing and printing characteristics of all paper stationeries.
• Textile Application:
Used to strengthen warp yarn and to improve resistance to abrasion while weaving. Also used to increase consistency in back filling improves the stiffness of the weave.
• Pharmaceutical Application:
Its used as a compressing agent in tablet manufacturing. Free from microbial bacteria, Corn starch is also used as a dusting agent in manufacturing of Surgical gloves.
• Adhesieve Application:
It’s used as an adhesive in pigmented coating for paper board and thereby improving the appearance of the paper by giving he required glossiness.
• Bakery Products:
Gives the necessary body, bulk and the sweetness to different bakery products. The hygroscopic properties impart longevity and freshness to its products.
• Leather Application:
Liquid glucose imparts glossiness, fineness and optimum weightage to leather goods.
• Ice Creams and Froze Desserts Application:
DMH lowers the freezing point in order to give a soft, creamy texture, and pleasant taste to its products. It has a unique ability to increase the solid substance of the product without unduly increasing the sweetness and hence improves the flavor of the product.
• Industrial Application:
Widely used in manufacturing of antibiotics such as streptomycin, refampicin. Also used in manufacturing of Sorbitol, mannitol and gluconates.
• Other Application:
It is used as a moisture holding agent in breads and as a dispersing agent in instant drink concentrates.
In India Following companies RIDDHI SIDDHI GLUOSE,ENGLISH INDIA CLAYTON,SUKHJIT GROUP,GUJARAT AMBUJA EXPORTS are main players,investors can consider stock picking for long term with good appreciation from current levels.This sector is stable and in expansion mode as the demand for it's products is ever increasing in the present scenario.
Monday, July 12, 2010
Saturday, July 10, 2010
PIRMAL HEALTHCARE Great prospect
After the news of transaction done by ABBOTT India to take one business formulation of PIRMAL healthcare and their 350 products for 17 thousand corers,Piramals are likely to merge Pirmal lifesciences with Pirmal healthcare ltd in future.As announced the company is going to reward it shareholders with special dividend in the range of 100-150 will be known 2-4weeks as they are going to get the first payment of transaction from Abbott.Currently the stock is trading around 500rs,looking at the track record of the promoters and their investment ideology future looks promising for this company they will surely build the company with the amount which they have received from Abbott and invest in takeovers and develop new products and explore new markets,According to me this is a safe defensive bet to invest for present and longterm.
Board to decide on use of funds post receipt of US$ 2.12 billion
Piramal Healthcare held its 63rd AGM in Mumbai on 9th July 2010. In the absence of Mr Ajay Piramal, Chairman, Mr R A Shah chaired the meet.
Highlights of the meet
* Piramal Healthcare has entering into definitive agreement with Abbott, USA to sell its domestic formulations (including mass market) business (Healthcare Solutions business) for total cash consideration of US$ 3.72 billion. Of the consideration, US$ 2.12 billion would be received on closure of the deal and further US$ 400 million would be receivable upon each of the subsequent 4 anniversaries of the closing, commencing in 2011.
* The management expects the deal closure in the next 4 - 6 weeks.
* Once the deal is closed, the board of directors would meet to decide on the future use of the funds received and what would be the reward to the shareholders.
* Domestic formulations business is conducted in India, Nepal and Srilanka and is being sold as going concern on a slump basis. The assets to be transferred include the company's manufacturing facilities' at Baddi, Himachal Pradesh and rights to approximately 350 brands and trademarks. The sale also involves transfer of the employees of the Domestic formulations business.
* For FY2010, the domestic formulation (healthcare solutions) business had revenues of Rs 2000.23 crore up 25% over previous year contributing 55% of the revenues of the Company.
* The capex for FY2011 would be about Rs 200 crore.
* There has been a fall in the employee strength in the R&D segment to 86 employees from 143 employees in the previous year. The main reason for the fall is transfer of the R&D staff to Piramal Life Sciences, which is the R&D arm of the group.
* The Company launched 32 new products in FY2010. The sales from new products launched over the last 24 months was Rs 150 crore for FY2010.
* Pharma Solutions segment revenues were down 17% at Rs 884.99 crore contributing to 24% of the revenues of the Company. The overseas business revenues fell 24% at Rs 509.11 crore contributing 14% of the revenues of the Company mainly due to closure of manufacturing facility at Huddersfield, UK. The Company is seeing recovery in the business environment towards the end of the year.
* Piramal Critical Care segment revenues grew 149% at Rs 327.67 crore contributing to 9% of the revenues of the Company. The segment saw the integration of Minrad International Inc and RxElite.
* Sevoflurane has seen increase in market share in US in volume terms to 17.8% from 4.7% in the previous year. The Company has completed dossier filings for 28 EU countries and has received first registration in Middle East & North Africa (MENA) region.
Board to decide on use of funds post receipt of US$ 2.12 billion
Piramal Healthcare held its 63rd AGM in Mumbai on 9th July 2010. In the absence of Mr Ajay Piramal, Chairman, Mr R A Shah chaired the meet.
Highlights of the meet
* Piramal Healthcare has entering into definitive agreement with Abbott, USA to sell its domestic formulations (including mass market) business (Healthcare Solutions business) for total cash consideration of US$ 3.72 billion. Of the consideration, US$ 2.12 billion would be received on closure of the deal and further US$ 400 million would be receivable upon each of the subsequent 4 anniversaries of the closing, commencing in 2011.
* The management expects the deal closure in the next 4 - 6 weeks.
* Once the deal is closed, the board of directors would meet to decide on the future use of the funds received and what would be the reward to the shareholders.
* Domestic formulations business is conducted in India, Nepal and Srilanka and is being sold as going concern on a slump basis. The assets to be transferred include the company's manufacturing facilities' at Baddi, Himachal Pradesh and rights to approximately 350 brands and trademarks. The sale also involves transfer of the employees of the Domestic formulations business.
* For FY2010, the domestic formulation (healthcare solutions) business had revenues of Rs 2000.23 crore up 25% over previous year contributing 55% of the revenues of the Company.
* The capex for FY2011 would be about Rs 200 crore.
* There has been a fall in the employee strength in the R&D segment to 86 employees from 143 employees in the previous year. The main reason for the fall is transfer of the R&D staff to Piramal Life Sciences, which is the R&D arm of the group.
* The Company launched 32 new products in FY2010. The sales from new products launched over the last 24 months was Rs 150 crore for FY2010.
* Pharma Solutions segment revenues were down 17% at Rs 884.99 crore contributing to 24% of the revenues of the Company. The overseas business revenues fell 24% at Rs 509.11 crore contributing 14% of the revenues of the Company mainly due to closure of manufacturing facility at Huddersfield, UK. The Company is seeing recovery in the business environment towards the end of the year.
* Piramal Critical Care segment revenues grew 149% at Rs 327.67 crore contributing to 9% of the revenues of the Company. The segment saw the integration of Minrad International Inc and RxElite.
* Sevoflurane has seen increase in market share in US in volume terms to 17.8% from 4.7% in the previous year. The Company has completed dossier filings for 28 EU countries and has received first registration in Middle East & North Africa (MENA) region.
Subscribe to:
Comments (Atom)